Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYLM's EV-to-OCF is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 8.07
vs ZYLM: -0.12
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Central Asia Lumeichun Biotechnology (OTCPK:ZYLM) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Central Asia Lumeichun Biotechnology's PE Ratio (TTM) for today is calculated as:
Central Asia Lumeichun Biotechnology's share price for today is $0.1636.
Central Asia Lumeichun Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.335.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Central Asia Lumeichun Biotechnology EV-to-OCF Related Terms
Central Asia Lumeichun Biotechnology EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Asia Lumeichun Biotechnology EV-to-OCF Chart
For the Farm Products subindustry, Central Asia Lumeichun Biotechnology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Asia Lumeichun Biotechnology EV-to-OCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Central Asia Lumeichun Biotechnology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Central Asia Lumeichun Biotechnology's EV-to-OCF falls into.
Central Asia Lumeichun Biotechnology's current Enterprise Value is $0.10 Mil.
Central Asia Lumeichun Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Asia Lumeichun Biotechnology (ZYLM) has a EV-to-OCF of 0.07 as of Sep. 21, 2026.
Is Central Asia Lumeichun Biotechnology's EV-to-OCF too high?
Central Asia Lumeichun Biotechnology's current EV-to-OCF is 0.07. The Consumer Packaged Goods industry median EV-to-OCF is 8.07. Central Asia Lumeichun Biotechnology's value of 0.07 is 99.1% below this industry median.
How does Central Asia Lumeichun Biotechnology's EV-to-OCF compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's EV-to-OCF of 0.07 can be compared against companies in the Consumer Packaged Goods industry. The industry median EV-to-OCF is 8.07. Central Asia Lumeichun Biotechnology's value of 0.07 is 99.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Consumer Packaged Goods company?
The median EV-to-OCF among Consumer Packaged Goods companies is 8.07, based on 2,001 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Asia Lumeichun Biotechnology's current EV-to-OCF of 0.07 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median EV-to-OCF is 8.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Asia Lumeichun Biotechnology's current EV-to-OCF is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current EV-to-OCF of 0.07. The current EV-to-OCF is 0.07 and 99.1% below the Consumer Packaged Goods industry median of 8.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current EV-to-OCF is 0.07 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYLM has been successfully added to your 
